SGMO
insider transactionsSANGAMO THERAPEUTICS, INC — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
-415.8K
0 buy · 415.8K sell
Net value · 90d
-$106.9K
$0 in · $106.9K out
Sentiment · 90d
Net selling
0% buying · 100% selling
Open-market trades · 90d
2
0 buy · 415.8K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Other·F
SVP, CHIEF LEGAL OFFICER, SECY
$703
4.0K sh · $0.17
Own -1%
-
Other·F
Sandy Macrae KEY
PRESIDENT, CEO AND DIRECTOR
$2.2K
12.6K sh · $0.17
Own -1%
-
Other·F
Principal Accounting Officer
$334
1.9K sh · $0.17
Own -1%
-
Other·F
SVP-CHIEF DEVELOPMENT OFFICER
$703
4.0K sh · $0.17
Own -1%
-
Other·F
Head of Research & Technology
$284
1.6K sh · $0.17
Own -1%
-
Sell·S
Head of Research & Technology
$17.7K
69.8K sh · $0.25
Own -38%
-
Sell·S
SVP-CHIEF DEVELOPMENT OFFICER
$89.2K
345.9K sh · $0.26
Own -51%
-
Grant·A
SVP, CHIEF LEGAL OFFICER, SECY
$0
800.0K sh
Own New
-
Grant·A
Sandy Macrae KEY
PRESIDENT, CEO AND DIRECTOR
$0
2.5M sh
Own New
-
Grant·A
Principal Accounting Officer
$0
225.0K sh
Own New
-
Grant·A
SVP-CHIEF DEVELOPMENT OFFICER
$0
800.0K sh
Own New
-
Grant·A
Head of Research & Technology
$0
225.0K sh
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 25, 2026 | Scott B. Willoughby | Other F | 4.0K | $703 |
| May 25, 2026 | Sandy Macrae KEY | Other F | 12.6K | $2.2K |
| May 25, 2026 | Nikunj Jain | Other F | 1.9K | $334 |
| May 25, 2026 | Nathalie Dubois-Stringfellow | Other F | 4.0K | $703 |
| May 25, 2026 | Gregory D Davis | Other F | 1.6K | $284 |
| Apr 22, 2026 | Gregory D Davis | Sell S | 69.8K | $17.7K |
| Apr 21, 2026 | Nathalie Dubois-Stringfellow | Sell S | 345.9K | $89.2K |
| Apr 1, 2026 | Scott B. Willoughby | Grant A | 800.0K | $0 |
| Apr 1, 2026 | Sandy Macrae KEY | Grant A | 2.5M | $0 |
| Apr 1, 2026 | Nikunj Jain | Grant A | 225.0K | $0 |
| Apr 1, 2026 | Nathalie Dubois-Stringfellow | Grant A | 800.0K | $0 |
| Apr 1, 2026 | Gregory D Davis | Grant A | 225.0K | $0 |
About SGMO insider trading
This page tracks insider transactions for SANGAMO THERAPEUTICS, INC (SGMO) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.